Insulet Q1 2026: Omnipod 5 Expands, Revenue Rises, and the Pod Set Keeps Climbing

Lede: A solid quarter that adds tempo to the Omnipod cadence

Insulet Corporation, the creator of the tubeless Omnipod insulin-pump ecosystem, reported a robust first quarter for 2026. The company generated revenue of $761.7 million, up 33.9% year over year and beating its own guidance at the high end as reported in the press release. Within that total, Total Omnipod revenue reached $758.4 million—a rise of 36.9% year over year (33.0% in constant currency)—driving a powerful contribution from the company’s flagship product line.

On the profitability side, Insulet posted GAAP operating income of $122.1 million (16.0% of revenue) and adjusted operating income of $133.5 million (17.5% of revenue), up 40 basis points and 110 basis points, respectively, versus the prior year. Net income came in at $91.1 million, or $1.30 per diluted share, while adjusted net income stood at $99.8 million, or $1.42 per diluted share—both materially higher than the year-ago period.

What drove the numbers: Omnipod and international momentum

The Omnipod contribution remains the headline. US Omnipod revenue totaled $515.6 million, up 28.3%, while international Omnipod revenue surged 59.4% (45.2% in constant currency) to $242.9 million. The company also reported a modest $3.3 million in Drug Delivery revenue, underscoring how the Omnipod platform still accounts for the vast majority of the top line.

The first-quarter execution also benefited from operating leverage as the company scales Omnipod deployment. The margin expansion—despite ongoing investments in R&D and international expansion—helps explain why management was comfortable raising the full-year revenue guidance for the business. In other words, the quarter wasn’t just about a lucky season; it’s a statement about a business model that scales with demand for a tubeless, actively managed insulin delivery platform.

Strategic highlights: Omnipod 5 expansion and ATTD data

• Launched Omnipod 5 and Omnipod Discover in five Middle East countries, expanding Omnipod 5’s availability to 19 countries.
• Presented data on the Omnipod 5 algorithm update at the ATTD International Conference. The latest algorithm update introduces a new 100 mg/dL target glucose option (six settings from 100–150 mg/dL) to improve personalization and time-in-range, with fewer interruptions during extended high-glucose events.
• Related enhancements aim to help users stay in automated mode longer, potentially improving user adherence and satisfaction with the system.

In a word, Insulet is betting not just on expanding the footprint of Omnipod 5, but on making the automation smarter and more adaptable to real-world glycemic variability. The ATTD data presentation signals a broader push to pair device hardware with smarter software—an ongoing arms race in diabetes technology.

Outlook and implications for investors

By raising its revenue forecast for the year, Insulet signals confidence in both product adoption and international growth. The company’s EPS trajectory—GAAP and adjusted—reflects not just topline strength but disciplined expense management and favorable mix as Omnipod scales.

For EPS consensus watchers, the results imply a favorable impulse for the stock, particularly if the company sustains Omnipod’s growth in international markets and converts robust top-line gains into improved margins. The strong earnings surprise versus internal guidance—coupled with a credible path to higher prosperity through Omnipod 5 enhancements—could place Insulet in a position to influence peers across the diabetes device space.

Sector peers might respond by accelerating product cadence, pushing deeper into automated insulin delivery and data-driven customization. The international push mirrors a broader shift in medical devices toward geographies with rising demand and improving reimbursement environments. The key question: can Insulet keep pace with the dual challenge of maintaining margin discipline while continuing to feed a high-velocity product cycle?

Risks and caveats

While the quarterly numbers are encouraging, investors should note that a sizeable portion of growth is linked to international expansion and the successful adoption of Omnipod 5. Currency fluctuations, regulatory changes in new markets, and potential delays in third-party reimbursement remain relevant risks. Additionally, ongoing R&D investments to support algorithmic advances and new product launches will shape margins over the coming quarters.

Conclusion: A quarterly chapter that may foreshadow a broader chapter

Insulet’s Q1 2026 results reinforce a narrative of deliberate growth through product differentiation and geographic expansion. By delivering strong revenue growth, meaningful margin expansion, and a compelling roadmap around Omnipod 5—augmented by ATTD data and international rollout—the company positions itself as a meaningful player in the evolving landscape of insulin-delivery technology. The next chapters will test whether the momentum can stick as the company raises its revenue forecast and further monetizes its automation investments.